StockNews.AI
CAPR
StockNews.AI
33 mins

CAPRICOR INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

1. Bragar Eagel & Squire is investigating claims against Capricor. 2. Long-term shareholders may discuss legal options due to potential fiduciary breaches. 3. A class action complaint was filed following a negative FDA response on July 11, 2025. 4. Capricor's stock declined significantly after receiving a Complete Response Letter from the FDA. 5. The complaint addresses misleading statements regarding deramiocel’s regulatory status.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The denial of the BLA and declining stock price indicate severe investor confidence erosion. Similar situations have historically led to steep declines in biotech stock prices.

How important is it?

The article directly discusses legal actions that affect investor confidence and stock value, making it highly significant.

Why Short Term?

Immediate legal issues and stock price response suggest short-term volatility. Previous cases show that legal troubles often have quick impacts on stocks.

Related Companies

DMDCAPR stock comparisons
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Capricor (CAPR) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Capricor between October 9, 2024 and July 10, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Capricor Therapeutics, Inc. (NASDAQ:CAPR) on behalf of long-term stockholders following a class action complaint that was filed against Capricor on July 17th, 2025 with a Class Period from October 9, 2024 and July 10, 2025. Our investigation concerns whether the board of directors of Capricor have breached their fiduciary duties to the company. Details: According to the complaint, defendants provided investors with material information concerning Capricor’s lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Defendants’ statements included, among other things, Capricor’s ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel.On July 11, 2025, Capricor issued a press release announcing it received a Complete Response Letter (CRL) from the FDA denying the BLA specifically citing it did not meet the statutory requirement for substantial evidence of effectiveness and the need for additional clinical data. Further, the CRL referenced outstanding items in the Chemistry, Manufacturing, and Controls section of the application.Following this news, the price of Capricor stock declined from $11.40 per share on July 10, 2025 to $7.64 per share on July 11, 2025. Next Steps: If you are a long-term stockholder of Capricor, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

Related News